Vanguard Group Inc Salarius Pharmaceuticals, Inc. Transaction History

Vanguard Group Inc

  • $5.46 Trillion
  • Q3 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022
SELL
$0.17 - $41.34 $39,379 - $9.58 Million
-231,647 Reduced 14.61%
1,353,373 $264,000
Q3 2021

Nov 12, 2021
BUY
$0.8 - $1.15 $32,236 - $46,340
40,296 Added 2.61%
1,585,020 $1.62 Million
Q2 2021

Aug 13, 2021
BUY
$1.02 - $1.52 $1.58 Million - $2.35 Million
1,544,724 New
1,544,724 $1.64 Million

About Salarius Pharmaceuticals, Inc.

SLRX Quotes by TradingView
  • Ticker SLRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 2,244,650
  • Market Cap $3.37M
  • Description
  • Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a ...
More about SLRX
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email